Follow
Giuseppe Aprile
Giuseppe Aprile
Department of Oncology, Vicenza, Italy
Verified email at aulss8.veneto.it
Title
Cited by
Cited by
Year
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
The Lancet 376 (9742), 687-697, 2010
67452010
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
The Lancet 383 (9911), 31-39, 2014
20552014
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ...
The Lancet 392 (10142), 123-133, 2018
8442018
Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease
K Qureshi, GA Abrams
World journal of gastroenterology: WJG 13 (26), 3540, 2007
794*2007
Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species
MG Perrelli, P Pagliaro, C Penna
World journal of cardiology 3 (6), 186, 2011
4042011
ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction …
YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ...
Lancet 376 (9742), 687-697, 2010
3172010
Clinical advances in the development of novel VEGFR2 inhibitors
C Fontanella, E Ongaro, S Bolzonello, M Guardascione, G Fasola, ...
Annals of translational medicine 2 (12), 2014
2282014
Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical …
C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ...
JAMA oncology 5 (3), 343-350, 2019
2112019
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
E Valtorta, C Martino, A Sartore-Bianchi, F Penaullt-Llorca, G Viale, ...
Modern Pathology 28 (11), 1481-1491, 2015
1972015
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ...
Annals of oncology 26 (10), 2092-2097, 2015
1832015
New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury
M Cinausero, G Aprile, P Ermacora, D Basile, MG Vitale, V Fanotto, ...
Frontiers in pharmacology 8, 354, 2017
1792017
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with …
C Cremolini, C Antoniotti, D Rossini, S Lonardi, F Loupakis, F Pietrantonio, ...
The Lancet Oncology 21 (4), 497-507, 2020
1532020
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
M Schirripa, F Bergamo, C Cremolini, M Casagrande, S Lonardi, G Aprile, ...
British journal of cancer 112 (12), 1921-1928, 2015
1462015
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised …
CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ...
The Lancet Oncology 20 (3), 420-435, 2019
1432019
Role of mammography, ultrasound and large core biopsy in the diagnostic evaluation of papillary breast lesions
F Puglisi, C Zuiani, M Bazzocchi, F Valent, G Aprile, B Pertoldi, ...
Oncology 65 (4), 311-315, 2003
1282003
REGARD Trial Investigators Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised …
CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ...
Lancet 383 (9911), 31-39, 2014
1252014
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 …
F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ...
Cancer 122 (4), 574-581, 2016
1182016
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas
F Puglisi, F Barbone, G Tell, G Aprile, B Pertoldi, C Raiti, MR Kelley, ...
Oncology reports 9 (1), 11-17, 2002
1182002
Fatigue: a main component of anemia symptomatology
A Sobrero, F Puglisi, A Guglielmi, O Belvedere, G Aprile, M Ramello, ...
Seminars in oncology 28, 15-18, 2001
1162001
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
H Blons, JF Emile, K Le Malicot, C Julié, A Zaanan, J Tabernero, E Mini, ...
Annals of oncology 25 (12), 2378-2385, 2014
1082014
The system can't perform the operation now. Try again later.
Articles 1–20